1. Home
  2. NSPR vs HOWL Comparison

NSPR vs HOWL Comparison

Compare NSPR & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InspireMD Inc.

NSPR

InspireMD Inc.

BUY

Current Price

$0.46

Market Cap

38.9M

Sector

Health Care

ML Signal

BUY

Logo Werewolf Therapeutics Inc.

HOWL

Werewolf Therapeutics Inc.

SELL

Current Price

$0.98

Market Cap

46.7M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
NSPR
HOWL
Founded
2005
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.9M
46.7M
IPO Year
2009
2021

Fundamental Metrics

Financial Performance
Metric
NSPR
HOWL
Price
$0.46
$0.98
Analyst Decision
Buy
Analyst Count
3
0
Target Price
★ $3.33
N/A
AVG Volume (30 Days)
108.5K
★ 514.3K
Earning Date
11-03-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 18.40
EPS
N/A
★ N/A
Revenue
★ $2,310,000.00
N/A
Revenue This Year
$9.14
N/A
Revenue Next Year
$105.44
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.46
$0.27
52 Week High
$2.41
$1.83

Technical Indicators

Market Signals
Indicator
NSPR
HOWL
Relative Strength Index (RSI) 24.56 60.91
Support Level N/A $0.86
Resistance Level $1.00 $0.99
Average True Range (ATR) 0.08 0.04
MACD -0.01 -0.00
Stochastic Oscillator 2.19 73.79

Price Performance

Historical Comparison
NSPR
HOWL

About NSPR InspireMD Inc.

InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.

About HOWL Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.

Share on Social Networks: